Moderna (MRNA)
(Delayed Data from NSDQ)
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.28 USD
-1.40 (-2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Zacks News
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Set for Continued Rally in 2020
by Zacks Equity Research
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alteryx, Moderna, Car-Mart, Bloom Energy and Target
5 Top Stocks That Surged Amid Volatility in the Last 7 Days
by Nalak Das
Volatility has gripped Wall Street since the past week owing to several conflicting news about the signing of an interim trade deal between the United States and China.
Moderna, Inc. (MRNA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Moderna, Inc. (MRNA).
Top Ranked Momentum Stocks to Buy for November 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 8th
Moderna (MRNA) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Moderna (MRNA) Stock
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Why Earnings Season Could Be Great for Moderna (MRNA)
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
by Ekta Bagri
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Options Traders Expect Huge Moves in Moderna (MRNA) Stock
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Moderna (MRNA) Announces Pipeline Progress, Shares Rise
by Zacks Equity Research
Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.